Astellas Pharma, Inc. (ALPMY)
16.84
+0.34
(+2.03%)
USD |
OTCM |
Nov 13, 16:00
Astellas Pharma Enterprise Value : 31.40B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 31.40B |
| November 12, 2026 | 30.80B |
| November 11, 2026 | 30.75B |
| November 10, 2026 | 30.62B |
| November 09, 2026 | 30.80B |
| November 06, 2026 | 29.57B |
| November 05, 2026 | 30.59B |
| November 04, 2026 | 29.92B |
| November 03, 2026 | 30.10B |
| November 02, 2026 | 30.27B |
| October 30, 2026 | 30.18B |
| October 29, 2026 | 29.89B |
| October 28, 2026 | 29.67B |
| October 27, 2026 | 29.78B |
| October 26, 2026 | 30.37B |
| October 23, 2026 | 29.80B |
| October 22, 2026 | 29.48B |
| October 21, 2026 | 29.32B |
| October 20, 2026 | 28.96B |
| October 19, 2026 | 28.35B |
| October 16, 2026 | 28.33B |
| October 15, 2026 | 27.93B |
| October 14, 2026 | 26.93B |
| October 13, 2026 | 27.00B |
| October 12, 2026 | 26.93B |
| Date | Value |
|---|---|
| October 09, 2026 | 26.93B |
| October 08, 2026 | 26.66B |
| October 07, 2026 | 26.73B |
| October 06, 2026 | 26.57B |
| October 05, 2026 | 26.68B |
| October 02, 2026 | 26.88B |
| October 01, 2026 | 27.09B |
| September 30, 2026 | 27.15B |
| September 29, 2026 | 28.67B |
| September 28, 2026 | 28.94B |
| September 25, 2026 | 29.42B |
| September 24, 2026 | 28.81B |
| September 23, 2026 | 29.14B |
| September 22, 2026 | 29.66B |
| September 21, 2026 | 29.41B |
| September 18, 2026 | 29.35B |
| September 17, 2026 | 29.37B |
| September 16, 2026 | 28.61B |
| September 15, 2026 | 28.78B |
| September 14, 2026 | 28.76B |
| September 11, 2026 | 28.24B |
| September 10, 2026 | 27.63B |
| September 09, 2026 | 28.01B |
| September 08, 2026 | 28.47B |
| September 04, 2026 | 29.12B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 94.93B |
| Daiichi Sankyo Co., Ltd. | 31.74B |
| Eisai Co., Ltd. | 8.931B |
| Chugai Pharmaceutical Co., Ltd. | 68.64B |
| Santen Pharmaceutical Co., Ltd. | 3.756B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 626.57M |
| Revenue (Quarterly) | 3.956B |
| Total Expenses (Quarterly) | 3.328B |
| EPS Diluted (Quarterly) | 0.3486 |
| Gross Profit Margin (Quarterly) | 74.48% |
| Profit Margin (Quarterly) | 15.84% |
| Earnings Yield | 8.08% |
| Operating Earnings Yield | 11.64% |
| Normalized Earnings Yield | 8.078 |